Assessment of concurrent neoplasms and a paraneoplastic association in MOGAD

Young Nam Kwon; Nanthaya Tisavipat; Yong Guo; Stephanie B. Syc-Mazurek; Ji Yeon Han; Jun Soon Kim; Kyomin Choi; Seong il Oh; Seok Jin Choi; Eunhee Sohn; Jeeyoung Oh; Seung Woo Kim; Ha Young Shin; Byung Chan Lim; Byoung Joon Kim; Kyung Seok Park; Jung Joon Sung; Se Hoon Kim; Sung Hye Park; Anastasia Zekeridou; Claudia F. Lucchinetti; Sean J. Pittock; John J. Chen; Eoin P. Flanagan; Sung Min Kim

doi:10.1002/acn3.52301

Assessment of concurrent neoplasms and a paraneoplastic association in MOGAD

Young Nam Kwon
, Nanthaya Tisavipat
, Yong Guo
, Stephanie B. Syc-Mazurek
, Ji Yeon Han
, Jun Soon Kim
, Kyomin Choi
, Seong il Oh
, Seok Jin Choi
, Eunhee Sohn
, Jeeyoung Oh
, Seung Woo Kim
, Ha Young Shin
, Byung Chan Lim
, Byoung Joon Kim
, Kyung Seok Park
, Jung Joon Sung
, Se Hoon Kim
, Sung Hye Park
, Anastasia Zekeridou

Claudia F. Lucchinetti, Sean J. Pittock, John J. Chen, Eoin P. Flanagan, Sung Min Kim

Department of Neurology

Yonsei University
Mayo Clinic Rochester, MN
Inha University
Seoul National University
Soonchunhyang University
Kyung Hee University
Chungnam National University
Konkuk University

Research output: Contribution to journal › Article › peer-review

2 Scopus citations

Abstract

Cases of myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease (MOGAD) co-occurring with neoplasms have been reported. In this international, retrospective cohort study in South Korea and the USA, 16 of 445 (3.6%) patients with MOGAD had concurrent neoplasm within 2 years of MOGAD onset, resulting in a standardized incidence ratio for neoplasm of 3.10 (95% confidence interval [CI], 1.77–4.81; P < 0.001) when compared to the age- and country-adjusted incidence of neoplasm in the general population. However, none of the nine tumor tissues obtained demonstrated MOG immunostaining. The slightly increased frequency without immunohistopathological evidence suggest with true paraneoplastic MOGAD is extremely rare.

Original language	English
Pages (from-to)	861-870
Number of pages	10
Journal	Annals of Clinical and Translational Neurology
Volume	12
Issue number	4
DOIs	https://doi.org/10.1002/acn3.52301
State	Published - Apr 2025

Access to Document

10.1002/acn3.52301

Cite this

Kwon, Y. N., Tisavipat, N., Guo, Y., Syc-Mazurek, S. B., Han, J. Y., Kim, J. S., Choi, K., Oh, S. I., Choi, S. J., Sohn, E., Oh, J., Kim, S. W., Shin, H. Y., Lim, B. C., Kim, B. J., Park, K. S., Sung, J. J., Kim, S. H., Park, S. H., ... Kim, S. M. (2025). Assessment of concurrent neoplasms and a paraneoplastic association in MOGAD. Annals of Clinical and Translational Neurology, 12(4), 861-870. https://doi.org/10.1002/acn3.52301

@article{dcfa7d97dab246f68949f4fa2d18ac70,

title = "Assessment of concurrent neoplasms and a paraneoplastic association in MOGAD",

abstract = "Cases of myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease (MOGAD) co-occurring with neoplasms have been reported. In this international, retrospective cohort study in South Korea and the USA, 16 of 445 (3.6\%) patients with MOGAD had concurrent neoplasm within 2 years of MOGAD onset, resulting in a standardized incidence ratio for neoplasm of 3.10 (95\% confidence interval [CI], 1.77{\textendash}4.81; P < 0.001) when compared to the age- and country-adjusted incidence of neoplasm in the general population. However, none of the nine tumor tissues obtained demonstrated MOG immunostaining. The slightly increased frequency without immunohistopathological evidence suggest with true paraneoplastic MOGAD is extremely rare.",

author = "Kwon, \{Young Nam\} and Nanthaya Tisavipat and Yong Guo and Syc-Mazurek, \{Stephanie B.\} and Han, \{Ji Yeon\} and Kim, \{Jun Soon\} and Kyomin Choi and Oh, \{Seong il\} and Choi, \{Seok Jin\} and Eunhee Sohn and Jeeyoung Oh and Kim, \{Seung Woo\} and Shin, \{Ha Young\} and Lim, \{Byung Chan\} and Kim, \{Byoung Joon\} and Park, \{Kyung Seok\} and Sung, \{Jung Joon\} and Kim, \{Se Hoon\} and Park, \{Sung Hye\} and Anastasia Zekeridou and Lucchinetti, \{Claudia F.\} and Pittock, \{Sean J.\} and Chen, \{John J.\} and Flanagan, \{Eoin P.\} and Kim, \{Sung Min\}",

note = "Publisher Copyright: {\textcopyright} 2025 The Author(s). Annals of Clinical and Translational Neurology published by Wiley Periodicals LLC on behalf of American Neurological Association.",

year = "2025",

month = apr,

doi = "10.1002/acn3.52301",

language = "English",

volume = "12",

pages = "861--870",

journal = "Annals of Clinical and Translational Neurology",

issn = "2328-9503",

publisher = "John Wiley \& Sons Inc.",

number = "4",

}

Kwon, YN, Tisavipat, N, Guo, Y, Syc-Mazurek, SB, Han, JY, Kim, JS, Choi, K, Oh, SI, Choi, SJ, Sohn, E, Oh, J, Kim, SW, Shin, HY, Lim, BC, Kim, BJ, Park, KS, Sung, JJ, Kim, SH, Park, SH, Zekeridou, A, Lucchinetti, CF, Pittock, SJ, Chen, JJ, Flanagan, EP & Kim, SM 2025, 'Assessment of concurrent neoplasms and a paraneoplastic association in MOGAD', Annals of Clinical and Translational Neurology, vol. 12, no. 4, pp. 861-870. https://doi.org/10.1002/acn3.52301

TY - JOUR

T1 - Assessment of concurrent neoplasms and a paraneoplastic association in MOGAD

AU - Kwon, Young Nam

AU - Tisavipat, Nanthaya

AU - Guo, Yong

AU - Syc-Mazurek, Stephanie B.

AU - Han, Ji Yeon

AU - Kim, Jun Soon

AU - Choi, Kyomin

AU - Oh, Seong il

AU - Choi, Seok Jin

AU - Sohn, Eunhee

AU - Oh, Jeeyoung

AU - Kim, Seung Woo

AU - Shin, Ha Young

AU - Lim, Byung Chan

AU - Kim, Byoung Joon

AU - Park, Kyung Seok

AU - Sung, Jung Joon

AU - Kim, Se Hoon

AU - Park, Sung Hye

AU - Zekeridou, Anastasia

AU - Lucchinetti, Claudia F.

AU - Pittock, Sean J.

AU - Chen, John J.

AU - Flanagan, Eoin P.

AU - Kim, Sung Min

PY - 2025/4

Y1 - 2025/4

N2 - Cases of myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease (MOGAD) co-occurring with neoplasms have been reported. In this international, retrospective cohort study in South Korea and the USA, 16 of 445 (3.6%) patients with MOGAD had concurrent neoplasm within 2 years of MOGAD onset, resulting in a standardized incidence ratio for neoplasm of 3.10 (95% confidence interval [CI], 1.77–4.81; P < 0.001) when compared to the age- and country-adjusted incidence of neoplasm in the general population. However, none of the nine tumor tissues obtained demonstrated MOG immunostaining. The slightly increased frequency without immunohistopathological evidence suggest with true paraneoplastic MOGAD is extremely rare.

AB - Cases of myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease (MOGAD) co-occurring with neoplasms have been reported. In this international, retrospective cohort study in South Korea and the USA, 16 of 445 (3.6%) patients with MOGAD had concurrent neoplasm within 2 years of MOGAD onset, resulting in a standardized incidence ratio for neoplasm of 3.10 (95% confidence interval [CI], 1.77–4.81; P < 0.001) when compared to the age- and country-adjusted incidence of neoplasm in the general population. However, none of the nine tumor tissues obtained demonstrated MOG immunostaining. The slightly increased frequency without immunohistopathological evidence suggest with true paraneoplastic MOGAD is extremely rare.

UR - https://www.scopus.com/pages/publications/85217565937

U2 - 10.1002/acn3.52301

DO - 10.1002/acn3.52301

M3 - Article

C2 - 39932929

AN - SCOPUS:85217565937

SN - 2328-9503

VL - 12

SP - 861

EP - 870

JO - Annals of Clinical and Translational Neurology

JF - Annals of Clinical and Translational Neurology

IS - 4

ER -

Assessment of concurrent neoplasms and a paraneoplastic association in MOGAD

Abstract

Access to Document

Other files and links

Fingerprint

Cite this